Catalyst Event

AbbVie Inc (ABBV) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/10/2026, 12:00:00 AM

OtherSentiment: Positive

The UK's National Institute for Health and Care Excellence (NICE) recommended Aquipta (atogepant) as an option for the acute treatment of migraine in adults on 2026-06-10.

Korean Translation

2026년 6월 10일 영국 국립보건임상연구원(NICE)이 아큅타(atogepant)를 성인 편두통 급성 치료 옵션으로 권고함.

Related Recent Events

View Full Timeline